Nastech and Amylin Sign Deal for Diabetes Nasal Spray
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 74 (Table of Contents)
Published: 6 Aug-2006
DOI: 10.3833/pdr.v2006.i74.478 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Nastech Pharmaceutical entered into a development and licensing agreement with Amylin Pharmaceuticals to develop a nasal spray formulation of exenatide (Byetta™) and synthetic exendin 4 compound for the treatment of type 2 diabetes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS